Nitric oxide and shock

Disease-a-Month

Volumn 43, Issue 5, 1997, Pages 279-348

  Kilbourn, R G ^a   Traber, D L ^a   Szabo, C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APAFANT; CREMOPHOR; CYCLIC GMP; CYTOKINE; INTERLEUKIN 1; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; PACLITAXEL; THIOUREA DERIVATIVE; TOXIN; TUMOR NECROSIS FACTOR; VASOCONSTRICTOR AGENT; ENZYME INHIBITOR;

ANAPHYLACTIC SHOCK; CARDIOGENIC SHOCK; CLINICAL FEATURE; ENDOTHELIUM INJURY; HEART PERFORMANCE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REVIEW; SEPTIC SHOCK; SHOCK; SIDE EFFECT; VASODILATATION; ANAPHYLAXIS; ANIMAL; BIOSYNTHESIS; CHEMICAL PHENOMENA; DRUG ANTAGONISM; ENDOTHELIUM; HEART; METABOLISM; OXYGEN CONSUMPTION; PHYSIOLOGY;

ANAPHYLAXIS; ANIMALS; CYCLIC GMP; CYTOKINES; DEPRESSION, CHEMICAL; ENDOTHELIUM; ENZYME INHIBITORS; HEART; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OXYGEN CONSUMPTION; SHOCK, CARDIOGENIC; SHOCK, SEPTIC; TOXINS, BIOLOGICAL; VASODILATION;

EID: 0031132386     PISSN: 00115029     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0011-5029(97)90028-6     Document Type: Review

References (317)

1. Bone R. Maumee: My Walden pond. JAMA 1996;276:1931.
2. Azimi G, Vincent J. Ultimate survival from septic shock. Resuscitation 1986;14: 245-53.
3. Parker M, Shelhamer J, Bacharach S, Green M, Natanson C, Frederick T, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100:483-90.
4. Groeneveld A, Bronsveld W, Thijs L. Hemodynamic determinants of mortality in human septic shock. Surgery 1986;99:140-53.
5. Groeneveld A, Nauta J, Thijs, L. Peripheral vascular resistance in septic shock: its relation to outcome. Intensive Care Med 1988;14:141-7.
6. Wiggers C. Physiology of shock. New York: Commonwealth Fund; 1950.
7. Guyton A. Overview of the circulation: medical physics of pressure, flow, resistance, and vascular compliance. In: Guyton A, editor. Human physiology and mechanisms of disease. 5th ed. Philadelphia: Saunders: 1992. p. 110-6.
8. Finley R, Duff J, Holliday R, Jones D. Capillary muscle blood flow in human sepsis. Surgery 1975;78:87-94.
9. Schumer W. Localization of the energy pathway block in shock. Surgery 1968;64:55-9.
10. Mela L, Bacalzo L, Miller L. Defective oxidative metabolism of rat liver mitochondria in hemorrhagic and endotoxic shock. Am J Physiol 1971;220:571-7.
11. Matthay M, Chatterjee, K. Bedside catheterization of the pulmonary artery: risks compared with benefit. Ann Intern Med 1988;109:826-34.
12. Gore D, Jahoor F, Hibbert J, DeMaria E. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996;224:97-102.
13. Welbourn R, Goldman G, O'Riordain M, Lindsay T, Paterson I, Kobsik L, et al. Role for tumor necrosis factor as a mediator of lung injury following lower torso ischemia. J Appl Physiol 1991;70:2645-9.
14. Cody C, Dunn D. Endotoxin in septic shock. In: Neugebauer E, Holaday J, editors. Handbook of mediators in septic shock. Boca Raton: CRC Press; 1993. p. 1-37.
15. Noshima S, Noda H, Herndon D, Traber L, Traber D. Left ventricular performance during continuous endotoxin induced hyperdynamic endotoxemia in sheep. J Appl Physiol 1993;74:1528-32.
16. Herberman RB. Cancer therapy with biological response modifiers. Clin Physiol Biochem 1987;5:238-48.
17. Gupta S. Cytokines: molecular and biological characteristics. Scand J Rheumatol 1988;76 Suppl: 189-201.
18. Waage A, Halstensen A, EspevikT. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
19. Casey L, Balk R, Bone R. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 1993;119:771-8.
20. Natanson C, Eichenholz P, Danner R, Eichacker P, Hoffman W, Kuo G, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989;169:823-32.
21. Okusawa S, Gelfand J, Ikejima T, Connolly R, Dinarello C. Interleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988;81:1162-72.
22. Nauts H. Bacteria and cancer: antagonisms and benefits. Cancer Surv 1989;8:713-23.
23. DeVita V, Hellman S, Rosenberg S. Biological therapy of cancer. 2nd ed. Philadelphia: Lippincott; 1995.
24. Lenk H. Clinical progress with biological response modifiers. Arch Geschwulstforsch 1991;61:61-5.
25. Remick DG, Kunkel SL. Toxic effects of cytokines in vivo. Lab Invest 1989;60:317-9.
26. Rosenberg SA, Lotze MT, Yang JC, Abersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 255 cancer patients. Ann Surg 1989;210:474-84.
27. Mier J, Vachino G. Klempner M, Aronson F, Noring R, Smith S, et al. Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 1990;76:1933-40.
28. Boccoli G, Masciulli E, Ruggeri E, et al. Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin-2 bolus treatment. Cancer Res 1990;50:5795-800.
29. Ognibene F, Rosenberg S, Skibber J, Shelhamer J, Lotze M, Parrillo J. Interleukin-2 hemodynamics mimic septic shock. Clin Res 1986;34:413A.
30. McCloskey R, Straube R, Sanders C, Smith S, Smith C, Group CTS. Treatment of septic shock with human monoclonal antibody HA-1A. Ann Intern Med 1994;121:1-5.
31. Young L, Gascon R, Alam S, Bermudez L. Monoclonal antibodies for the treatment of gram-negative infections. Rev Infect Dis 1989;11:S1564-71.
32. Fisher C, Slotner G, Opal S, Pribble J, Bone R, Emmanuel G. Initial evaluation of human recombinant IL-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled, multicenter trial. Crit Care Med 1994;22: 12-21.
33. Zeigler EJ, Fisher CJ, Sprung CL, et al. Treatment of gram negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429-36.
34. Wherry J, Wenzel R, Wunderink R, Silverman H, Nasraway S. Monoclonal antibody to human TNF: multicenter efficacy and safety study in patients with sepsis syndrome. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Oct. 17-20, 1993, New Orleans; Abstract 696:246.
35. 100 septic shock following therapy with antibody to tumor necrosis factor. Circ Shock 1990;30: 279-92.
36. Wakabayashi G, Gelfand JA, Burke JF, Thompson RC, Dinarello CA. A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991;5:338-43.
37. Kilbourn RG, Belloni P. Endothelial cell production of nitrogen oxides in response to interferon gamma in combination with tumor necrosis factor, interleukin-1, or endotoxin. J Natl Cancer Inst 1990;82:772-6.
38. Ochoa J, Udekwu A, Billiar T. Nitrogen oxide levels in patients after trauma and during sepsis. Ann Surg 1991;214:621-6.
39. Endo S, Inada K, Nakae H, et al. Nitrite/nitrate oxide (NOX) and cytokine levels in patients with septic shock. Res Commun Mol Pathol Pharmacol 1996;91:347-56.
40. Neilly I, Copland M, Haj M. Plasma nitrate concentrations in neutropenic and non-neutropenic patients with suspected septicemia. Br J Haematol 1995;89:199-202.
41. Hibbs J, Westenfelder C, Taintor R, et al. Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 1992;89:867-77.
42. Ochoa J, Curti B, Peitzman A, et al. Increased circulating nitrogen oxides after human tumor immunotherapy correlate with toxic hemodynamic changes. J Natl Cancer Inst 1992;84:864-7.
43. Butler A, Flitney F, Williams D. NO, nitrosonium ions, nitroxide ions, nitrosothiols and iron-nitrosyls in biology: a chemist's perspective. Trends Pharmacol Sci 1995; 16:18-22.
44. Stamler J, Jaraki O, Osborne J, Simon D, Keaney J, Vita J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992;89:7674-7.
45. Stadler J, Harbrecht B, DiSilvio M, Curran R, Jordan M, Simmons R, et al. Endogenous nitric oxide inhibits the synthesis of cyclooxygenase products and interleukin-6 by rat Kupffer cells. J Leukoc Biol 1993;53:165-72.
46. Brune B, Dimmeler S, Molina Y, Vedia L, Lapetina E. Nitric oxide: a signal for ADP-ribosylation of proteins. Life Sci 1993;54:61-70.
47. Zhang J, Dawson V, Dawson T, Snyder S. Nitric oxide activation of poly ADP-ribose synthetase in neurotoxicity. Science 1994;263:687-9.
48. Radons J, Heller B, Burkle A, Hartmann B, Rodriguez M, Kroncke K, et al. Nitric oxide toxicity in islet cells involves poly ADP-ribose polymerase activation and concomitant NAD depletion. Biochem Biophys Res Comm 1994;199:1270-7.
49. Zingarelli B, O'Connor M, Wong H, Salzman A, Szabó C. Peroxynitrite-raediated DNA strand breakage activates poly-ADP ribosyl synthetase and causes cellular energy depletion in macrophages stimulated with bacterial lipopolysaccharide. J Immunol 1996;156:350-8.
50. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6: 3051-64.
51. Marietta M. Mammalian synthesis of nitrite, nitrate, nitric oxide and N-nitrosating agents. Chem Res Toxicol 1988;1:249-57.
52. Marietta M. Nitric oxide synthase structure and mechanism. J Biol Chem 1993;268: 12231-4.
53. Vane J. 1993: The Croonian lecture - the endothelium; maestro of the blood circulation. Proc R Soc Lond 1994;B343:225-46.
54. Dinerman J, Lowenstein C, Snyder S. Molecular mechanisms of nitric oxide production: potential relevance to cardiovascular disease. Circ Res 1993;73:217-22.
55. Bredt D, Snyder S. Isolation of nitric oxide synthetase, a calmodulin - requiring enzyme. Proc Natl Acad Sci USA 1990;87:682-5.
56. Bredt D, Snyder S. Nitric oxide: a physiologic messenger molecule. Ann Rev Biochem 1994;63:175-95.
57. Garthwaite J, Boulton C. Nitric oxide signalling in the central nervous system. Ann Rev Physiol 1995;57:683-706.
58. Marcin N, Papapetropoulos A, Catravas J. Tyrosine kinase inhibitors suppress endotoxin- and IL-1 beta-induced NO synthesis in aortic smooth muscle cells. Am J Physiol 1993;265:H1014-8.
59. Xie Q, Nathan C. The high-output nitric oxide pathway: role and regulation. J Leukoc Biol 1994;56:576-82.
60. Szabó C, Thiemermann C. Mechanism of the induction of nitric oxide synthase. Adv Pharmacol 1995;34:113-53.
61. Szabó C. Alterations in nitric oxide production in various forms of circulatory shock. New Horiz 1995;3:2-32.
62. Wu C, Chen S, Szabó C, Thiemermann C, Vane J. Aminoguanidine attenuates the delayed circulatory failure and improves survival in rodent models of endotoxic shock. Br J Pharmacol 1995;114:1666-72.
63. Grisham M, Specian R, Zimmerman T. Effects of nitric oxide synthase inhibition on the pathophysiology observed in a model of chronic granulomatous colitis. J Pharmacol Exp Ther 1994;271:1114-21.
64. Zielasek J, Jung S, Gold R, Liew F, Toyka K, Hartung H. Administration of nitric oxide synthase inhibitors in experimental autoimmune neuritis and experimental autoimmune encephalomyelitis. J Neuroimmunol 1995;58:81-8.
65. MacMicking J, Nathan C, Hom G, et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995;81:641-50.
66. Wei X, Charles I, Smith A, et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995;375:408-11.
67. Fukuto J, Komori Y. The enzymology and manipulation of nitric oxide synthase. Ann Rev Med Chem 1994;29:83-92.
68. Stuehr D, Griffith OW. Mammalian nitric oxide synthases. Adv Enzymol 1992;65:287-346.
69. Spink J, Cohen J, Evans T. The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase: activation by nuclear factor-kappa B. J Biol Chem 1995;270:29541-7.
70. Hecker M, Preiss C, Schini-Kerth V, Busse R. Antioxidants differentially affect nuclear factor kappa B-mediated nitric oxide synthase expression in vascular smooth muscle cells. FEBS Lett 1996;380:224-8.
71. Hirokawa K, O'Shaughnessy K, Moore K, Ramrakha P, Wilkins M. Induction of nitric oxide synthase in cultured vascular smooth muscle cells: the role of cyclic AMP. Br J Pharmacol 1994;112:396-402.
72. InonueT, Fukuo K, NakahashiT, Hata S, Morimoto S, OgiharaT. cGMP upregulates nitric oxide synthase expression in vascular smooth muscle cells. Hypertension 1995;25:711-4.
73. Nakayama I, Kawahara Y, Tsuda T, Koide M, Yokoyama M. Cyclic AMP elevating agents synergize with inflammatory cytokines to induce an inducible type of nitric oxide synthase in cultured vascular smooth muscle cells. Ann NY Acad Sci 1995;748: 586-9.
74. Paya D, Gray G, Fleming I, Stoclet J. Effect of dexamethasone on the onset and persistence of vascular hyporeactivity induced by E. coli lipopolysaccharide in rats. Circ Shock 1993;41:103-12.
75. Szabó C, Mitchell J, Gross S, Thiemermann C, Vane J. Nifedipine inhibits endotoxin-mediated nitric oxide synthase induction. J Pharmacol Exp Ther 1993;256:674-80.
76. Schini V, Catovsky S, Schray-Utz B, Busse R, Vanhoutte P. Insulin like growth factor I inhibits induction of nitric oxide synthase in vascular smooth muscle cells. Circ Res 1994;74:24-32.
77. Geng Y, Wu Q, Hansson G. Protein kinase C activation inhibits cytokine-induced nitric oxide synthesis in vascular smooth muscle cells. Biochim Biophys Acta 1994;123:125-32.
78. Durante W, Kroll M, Orloff G, Cunningham, J, Scott-Burden T, Vanhoutte P, et al. Regulation of interleukin-1-beta-stimulated inducible nitric oxide synthase expression in cultured vascular smooth muscle cells by hemostatic proteins. Biochem Pharmacol 1996;51:847-53.
79. Szabó C, Wu C, Gross S, Thiemermann C, Perretti M, Vane J. Interleukin-1 contributes to the induction of nitric oxide synthase by endotoxin in vivo. Eur J Pharmacol 1993;250:157-60.
80. Thiemermann C, Wu C, Szabó C, Perretti M, Vane J. Tumour necrosis factor is an endogenous mediator of the induction of nitric oxide synthase in endotoxin shock in the rat. Br J Pharmacol 1993;110:177-82.
81. Paya D, Gray G, Stoclet J. Effects of methylene blue on blood pressure and reactivity to norepinephrine in endotoxemic rats. J Cardiovasc Pharmacol 1993;21:926-30.
82. Perrella M, Hsieh C, Lee W, et al. Arrest of endotoxin-induced hypotension by transforming growth factor beta. Proc Natl Acad Sci USA 1996;93:2054-9.
83. Katsuki S, Arnold W, Mittal C, Murad F. Stimulation of guanylate cyclase by sodium nitroprusside, nitroglycerin and nitric oxide in various tissue preparations and comparison to the effects of sodium azide and hydroxylamine. J Cyclic Nucleotide Res 1977;3:23-5.
84. Ignarro LJ. Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 1991;41:485-90.
85. 2+ by sarcoplasmic reticulum in vascular smooth muscle. Circ Res 1988;62: 962-4.
86. Beasley D, Schwartz JH, Brenner BM. Interleukin-1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. J Clin Invest 1991;87:602-8.
87. Schmidt H, Lohmann S, Walter U. The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. Biochem Biophys Acta 1993; 1178:153-75.
88. Marczin N, Tekeres M, Salzman A. Szabó C. Methylene blue infusion in septic shock. Crit Care Med 1996;23:1936-8.
89. Moro M, Russel R, Cellek S, Lizasoain I, Su Y, Darley-Usmar V, et al. cGMP mediates the vascular and platelet actions of nitric oxide: confirmation using an inhibitor of the soluble guanylyl cyclase. Proc Natl Acad Sci USA 1996;93:1480-5.
90. Geng Y, Hansson G, Holme E. Interferon-gamma and tumor necrosis factor synergize to induce nitric oxide production and inhibit mitochondrial respiration in vascular smooth muscle cells. Circ Res 1992;71:1268-76.
91. Szabó C. DNA strand breakage and activation of poly-ADP ribosyl-transferase: a cytotoxic pathway triggered by peroxynitrite. Free Radic Biol Med 1996;21:855-69.
92. Beckman J, BeckmanT, Chen J, Marshall P, Freeman B. Apparent hydroxyl radical production by peroxynitrite: implication for endothelial injury from nitric oxide and Superoxide. Proc Natl Acad Sci USA 1990;87:1620-4.
93. Ischiropoulos H, Zhu L, Beckman J. Peroxynitrite formation from macrophage-derived nitric oxide. Arch Biochem Biophys 1992;298:446-51.
94. Szabó C. The role of peroxynitrite in the pathophysiology of shock, inflammation and ischemia-reperfusion injury. Shock 1996;6:79-88.
95. Viner R, Huhmer A, Bigelow D, Schoneich C. The oxidative inactivation of sarcoplasmic reticulum Ca(2+)-ATPase by peroxynitrite. Free Radic Res 1996;24: 243-59.
96. Salvemini D, Misko T, Masferrer J, Seibert K, Currie M, Needleman P. Nitric oxide activates cyclooxygenase enzymes. Proc Natl Acad Sci USA 1993;90:7240-4.
97. Bolotina V, Najibi S, Palacino J, Pagano P, Cohen R. Nitric oxide directly activates calcium-dependent potassium channels in vascular smooth muscle. Nature 1994;368: 850-83.
98. Murphy M, Brayden J. Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 1995;486:47-58.
99. Hibbs J, Vavrin Z, Taintor R. L-Arginine is required for expression of the activated macrophage effector mechanism causing selective metabolic inhibition in target cells. J Immunol 1987;138:550-65.
100. G-methylarginine. Biochem Biophys Res Commun 1990;170: 96-103.
101. G-nitro-L-arginine act as prodrugs in their inhibition of inducible nitric oxide synthase. In: Moncada S, Busse R, Higgs EA, editors. The biology of nitric oxide, vol. 4. Enzymology. biochemistry and immunology. London: Portland Press: 1995. p. 4-7.
102. Abu-Soud H, Feldman P, Clark P Stuehr D. Electron transfer in the nitric-oxide synthases. J Biol Chem 1994;269:32318-26.
103. G-methyl-L-arginine functions as an alternative substrate and mechanism-based inhibitor of nitric oxide synthase. Biochemistry 1995;32:9677-85.
104. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-5.
105. 6-(l-iminoethyl) lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994;37: 3886-8.
106. Connor J, Manning P, Settle S, Moore W, Jerome G, Sebber R, et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995;273:15-24.
107. Laszlo F, Whittle B, Moncada S. Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestine by nitric oxide synthase inhibitors. Br J Pharmacol 1994;111:1309-15.
108. Szabó C, Southan G, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methyl isothiourea sulfate, a novel, potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 1994;91:12472-6.
109. G-monomethyl-L-arginine inhibits endotoxin-induced nitrate/nitrate biosynthesis while promoting hepatic damage. J Leukoc Biol 1990;48:565-9.
110. Ma T, Ischiropoulos H, Brass C. Endotoxin-stimulated nitric oxide production increases injury and reduces rat liver chemiluminescence during reperfusion. Gastroenterology 1995;108:463-9.
111. Misko T, Moore W, Kasten T, Nickols D, Corbett J, Tilton R, et al. Selective inhibition of the inducible NO synthase by aminoguanidine. Eur J Pharmacol 1993;233: 119-25.
112. Hasan K, Heesen B, Corbett J, McDaniel M, Chang K, Allison W, et al. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993;249:101-6.
113. Garvey E, Oplinger J, Tanoury G, Sherman P. Fowler M, Marshall S, et al. Potent and selective inhibition of human nitric oxide synthases. J Biol Chem 1994;269: 26669-76.
114. Southan G, Szabó C, Thiemermann C. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 1995;114:510-6.
115. Southan G, Szabó C, O'Connor M, Salzman A, Thiemermann C. Amidines are potent inhibitors of constitutive and inducible nitric oxide synthases: preferential inhibition of the inducible isoform. Eur J Pharmacol 1995;291:311-8.
116. Southan G, Zingarelli B, O'Connor M, Salzman A, Szabó C. Spontaneous rearrangement of aminoalkylguanidines into mercaptoalkylguanidines: a novel class of nitric oxide synthase inhibitors with selectivity towards the inducible isoform. Br J Pharmacol 1996;117:619-32.
117. Szabó C, Bryk R, Zingarelli B, Southan G, Gahman T, Bhat V, et al. Pharmacological characterization of guanidinoethyldisulphide (GED), a novel inhibitor of nitric oxide synthase with selectivity towards the inducible isoform. Br J Pharmacol 1996;118:1659-68.
118. Wolff D, Lubeskie A. Aminoguanidine is an isoform-selective, mechanism-based inactivator of nitric oxide synthase. Arch Biochem Biophys 1995;316:290-301.
119. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 1995;44:360-4.
120. Cross A, Misko T, Lin R, Hickey W, Trotter J, Tilton R. Aminoguanidine, an inhibitor of inducible nitric oxide synthase, ameliorates experimental autoimmune encephalomyelitis in SJL mice. J Clin Invest 1994;93:2684-90.
121. Corbett A, Tilton R, Chang K. Aminoguanidine, a novel inhibitor of nitric oxide formation, prevents diabetic vascular dysfunction. Diabetes 1992;41:552-6.
122. Griffiths M, Messent M, MacAllister R, Evans T. Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993;110:963-8.
123. Booke M, Schenarts P, Shin C, Biondo N, McGuire R, Traber L, et al. A new non-amino acid inhibitor of nitric oxide synthase (3936W920) in hyperdynamic ovine sepsis. Shock 1995;3(1 Suppl):S72.
124. Thiemermann C, Rutten H, Wu C, Vane J. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br J Pharmacol 1995;116:2845-51.
125. YoshidaT, Limmroth V, Irikura K, Moskowitz M. The NOS inhibitor, 7-nitroindazole, decreases focal infarct volume but not the response to topical acetylcholine in pial vessels. J Cereb Blood Flow Metab 1994;14:924-9.
126. Schulz J, Matthews R, Muqit M, Browne S, Beal M. Inhibition of neuronal nitric oxide synthase by 7-nitroindazole protects against MPTP-induced neurotoxicity in mice. J Neurochem 1995;64:936-9.
127. Julou-Schaeffer G, Gray G, Fleming I, Schott C, Parratt J, Stoclet J. Loss of vascular responsiveness induced by endotoxin involves L-arginine pathway. Am J Physiol 1990;259:H1038-43.
128. Rees DD, Cellek S, Palmer RM, Moncada S. Dexamethasone prevents the induction by endotoxin of a nitric oxide synthase and the associated effects on vascular tone: an insight into endotoxin shock. Biochem Biophys Res Commun 1990;173:541-7.
129. Gray G, Julou-Schaeffer G, Oury K, Fleming I, Parratt J, Stoclet J. An L-arginine derived factor mediates endotoxin-induced vascular hyposensitivity to calcium. Eur J Pharmacol 1990;67:119-24
130. Li T, Croce K, Winquist R. Regional differences in the effects of septic shock on the vessel reactivity in the rabbit. J Pharmacol Exp Ther 1992;261:959-63.
131. G-amino-arginine inhibits interleukin-la-induced nitric oxide synthase in vascular smooth muscle and fully reverses interleukin-la-induced hypotension. J Natl Cancer Inst 1992;84:1008-16.
132. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 1990;87:3629-32.
133. G-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2 mediated hypotension in dogs. J Appl Physiol 1994;76:1130-7.
134. G-methyl-L-arginine. an inhibitor of nitric oxide synthesis. Biochem Biophys Res Commun 1990;172:1132-8.
135. Fleming I, Gray G, Julou-Schaeffer G, Parratt J, Schott C, Stoclet J. Impaired vascular reactivity in the rat following endotoxin treatment can be endothelium independent, yet involves the L-arginine pathway. J Physiol 1989;423:105P-7P.
136. Hinder F, Booke M, Traber L, Matsumoto N, Nishida K, Rogers S, et al. Nitric oxide synthase inhibition during experimental sepsis improves renal excretory function in the presence of chronically elevated atrial natriuretic peptide. Crit Care Med 1996:24:131-6.
137. Nava E, Palmer R, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial? Lancet 1991;338:1555-7.
138. Teale D, Atkinson A. Inhibition of nitric oxide synthesis improves survival in a murine model of sepsis that is not cured by antibiotic alone. J Antimicrob Chemother 1992;30:839-42.
139. Klemm P, Thiemermann C, Winklmaier G, Martorana P, Henning R. Effects of nitric oxide synthase inhibition combined with nitric oxide inhalation in a porcine model of endotoxin shock. Br J Pharmacol 1995;114:363-8.
140. Kilbourn R, Szabó C, Taber D. Beneficial versus detrimental effects of nitric oxide synthase inhibitors in circulatory shock: lessons learned from experimental and clinical studies. Shock 1997;7:235-46.
141. G monomethyl-L-arginine (NMA) restores arterial blood pressure but reduces cardiac output in a canine model of endotoxic shock. Biochem Biophys Res Commun 1991;178:1135-40.
142. Henderson J, Statman R, Cunningham J. The effects of nitric oxide inhibition on regional hemodynamics during hyperdynarnic endotoxemia. Arch Surg 1994;129:1271-5.
143. Pastor C, Teisseire B, Vicaut E. Effects of L-arginine and L-nitro arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994;22:465-9.
144. Mulder M, VanLambalgen A, Huisman L. Protective role of NO in the regional hemodynamic changes during acute endotoxemia in rats. Am J Physiol 1994;266:H1558-64.
145. Minnard E, Shou J, Naama H. Inhibition of nitric oxide synthesis is detrimental during endotoxemia. Arch Surg 1994;129:142-8.
146. G-amino-L-arginine, an inhibitor of nitric oxide synthase, increases lethality in canine endotoxic shock. Clin Res 1991;39:321A.
147. G-nitro-L-arginine methyl ester) in a murine sepsis model. Arch Surg 1994;130:410-4.
148. Tiao G, Ogle C. Detrimental effects of nitric oxide synthase inhibition may be caused by high levels of tumor necrosis factor and interleukin-6. Surgery 1994;116:332-8.
149. Lorente J, Landin L, De Pablo R, Renes E, Liste D. L-arginine pathway in the sepsis syndrome. Crit Care Med 1993;21:1287-95.
150. Spain D, Wilson M, Garrison R. Nitric oxide synthase inhibition exacerbates sepsis-induced renal hypoperfusion. Surgery 1994;116:322-31.
151. G-monomethyl-L-arginine (L-NMMA:546C88) improves survival in a conscious instrumented mouse model of endotoxic shock. Endothelium 1995;3(Suppl):S116.
152. Liu S, Adcock I, Old R, Barnes P, Evans T. Differential regulation of the constitutive and inducible nitric oxide synthase mRNA by lipopolysaccharide treatment in vivo in the rat. Crit Care Med 1996;24:1219-25.
153. Myers P, Wright T, Tanner M, Adams HR. EDRF and nitric oxide production in cultured endothelial cells: direct inhibition by E coli endotoxin. Am J Physiol 1992;262: H710-8.
154. Spath J, Sloane P, Gee M, Albertine K. Loss of endothelium-dependent vasodilation in the pulmonary vessels of sheep after prolonged endotoxin. J Appl Physiol 1994;76:361-9.
155. MacNaul K, Hutchinson N. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun 1993;196:1330-4.
156. Meyer J, Traber L, Nelson S, Lentz C, Nakazawa H, Herndon D, et al. Reversal of hyperdynamic response to continuous endotoxin administration by inhibition of NO synthesis. J Appl Physiol 1992;73:324-8.
157. Meyer J, Lentz C, Stothert J, Traber L, Herndon D, Traber D. Effects of nitric oxide synthesis inhibition in hyperdynamic endotoxemia. Crit Care Med 1994;22:306-12.
158. Lingnau W, McGuire R, Dehring D, Traber L, Linares H, Nelson S, et al. Changes in regional hemodynamics after nitric oxide inhibition during ovine bacteremia. Am J Physiol 1996;270:R207-16.
159. Booke M, Hinder F, McGuire R, Traber L, Traber D. Nitric oxide synthase inhibition versus norepinephrine in ovine sepsis: effects on regional blood flow. Shock 1996;5:362-70.
160. Booke M, Hinder F, Traber L, McGuire R, Traber D. Ethylisothiourea, a nonaminoacid inhibitor of nitric oxide synthase, reverses septic vasodilation in sheep. Shock 1995;4:274-81.
161. Meyer J, Hinder F, Stothert J, Traber L, Herndon D, Flynn J, et al. Increased organ blood flow in chronic endotoxemia is reversed by nitric oxide synthase inhibition. J Appl Physiol 1994;76:2785-93.
162. Booke M, Meyer J, Lingnau W, Hinder F, Traber L, Traber D. Use of nitric oxide synthase inhibitors in animal models of sepsis. New Horiz 1995;3:123-38.
163. Calvert D, Lum B. The effects of hemorrhagic shock upon blood pressure responses to adrenergic agents and upon tissue catecholamines. J Pharmacol Exp Ther 1968;159: 74-81.
164. Bond R, Johnson G III. Vascular adrenergic interactions during hemorrhagic shock. Fed Proc 1985;44:281-9.
165. Perbeck L, Hedquist P. Blood pressure responses associated with hemorrhagic shock in anesthetized rats. Acta Physiol Scand 1982:148:3-8.
166. Westenberge RU, Thanner S, Ruf H, Gersonde K, Sutter G, Trentz O. Formation of free radicals and nitric oxide derivative of hemoglobin in rats during shock syndrome. Free Radical Res Commun 1990;11:167-78.
167. Zingarelli B, Squadrito F, Altavilla D, Calapai G, Campo GM, Calo M, et al. Evidence for a role of nitric oxide in hypovolemic hemorrhagic shock. J Cardiovasc Pharmacol 1992;19:982-6.
168. Thiemermann C, Szabó C, Mitchell J. Vane J. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc Natl Acad Sci USA 1993;90:267-71.
169. Kelly E, Shah NS, Norgan NN, Watkins SC, Peitzman AB, BilliarTR. Physiologic and molecular characterization of the role of nitric oxide in hemorrhagic shock. Shock 1997;7:157-63.
170. Zingarelli B, Salzman A, Szabó C. Mercapto-ethyl-guanidine, a selective inhibitor of the inducible isoform of nitric oxide synthase has beneficial effects in a rat model of delayed hemorrhagic shock. Crit Care Med 1997;5(suppl):A90.
171. Naziri W, Pietsch JD, Appel SH, Cheadle WG, Bergamini TM, Polk HCJ. Hemorrhagic shock induced alterations in circulating and bronchoalveolar macrophage nitric oxide production. J Surg Res 1995;59:146-52.
172. Zhu XH, Zhu XL, Zellweger R, Ayala A, Chaudry IH. Inducible nitric oxide synthase mRNA expression in murine peritoneal macrophages, splenic macrophages and Kupffer cells following hemorrhage. Shock 1995;2(suppl):13.
173. Szabó C, Thiemermann C. Role of nitric oxide in haemorrhagic. traumatic and anaphylactic shock and in thermal injury [invited opinion]. Shock 1994;2:145-55.
174. Szabó C, Salzman AL, Ischiropoulos H. Peroxynitrite mediated oxidation of dihydrorhodamine 123 occurs in early stages of endotoxic and hemorrhagic shock and ischemia-reperfusion injury. FEBS Lett 1995;372:229-32.
175. LaRocco M, Rodriguez L, Chen Y, Smith G, Russell D. Myers S, et al. Re-evaluation of the linkage between acute hemorrhagic shock and bacterial translocation in the rat. Circ Shock 1993;40:212-20.
176. Yao YM, Bahrami S, Leichtfried G, Redl H, Schlag G. Significance of NO in hemorrhage-induced hemodynamic alterations, orsan injury, and mortality in rat. Am J Physiol 1996;270:H1616-23.
177. Szabó C, Mitchell J, Gross S, Thiemermann C, Vane J. Platelet activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ Res 1993;73:991-9.
178. Cristol J, Thiemermann C, Mitchell J, Walder C, Vane J. Support of renal blood flow after ischaemic-reperfusion injury by endogenous formation of nitric oxide and of vasodilator cyclooxygenase metabolites. BrJ Pharmacol 1993;109:188-94.
179. Archer S, Freude K, Shultz P. Effect of graded hypoxia on the induction and function of inducible nitric oxide synthase in rat mesangial cells. Circ Res 1995;77:21-8.
180. Melillo G, Taylor L, Brooks A, Cox G, Vareso L. Regulation of inducible nitric oxide synthase expression in interferon-gamma treated murine macrophages cultured under hypoxic conditions. J Immunol 1996;157:2638-44.
181. Chiu T, Reid IA. Elfect of inhibition of nitric oxide synthesis on the cardiovascular and endocrine responses to hemorrhage in conscious rabbits. Hypertens Res 1995;18:55-61.
182. Koch MA, Hasser EM, Schadt A. Influence of nitric oxide on the hemodynamic response to hemorrhage in conscious rabbits. Am J Physiol 1995:268:R171-82.
183. Palmer R, Bridge L, Foxwell N, Moncada S. The role of nitric oxide in endothelial cell damage and its inhibition by glucocorticoids. Br J Pharmacol 1992;105:11-2.
184. G-methyl-L-arginine restores arterial pressure in hemorrhaged rats. Circ Shock 1993;40:47-52.
185. Lieberthal W, McGarry A, Sheils J, Valeri R. Nitric oxide inhibition in rats improves blood pressure and renal function during hypovolemic shock. Am J Physiol 1991;261: F868-72.
186. Harbrecht BG, Wu B, Watkins SC, Marshall HP, Peitzman AB, Billiar TR. Inhibition of nitric oxide synthase during hemorrhagic shock increases hepatic injury. Shock 1995;4:332-7.
187. Brown IP, Williams RL, Mckirnan M, Limjoco UR, Gray CG. Nitric oxide synthesis inhibition does not improve the hemodynamic response to hemorrhagic shock in dehydrated conscious swine. Shock 1995;3:292-8.
188. Vromen A, Szabó C, Southan G, Salzman AL. Protective effects of isopropylisothiourea, a potent inhibitor of constitutive nitric oxide synthase in rodent and porcine models of hemorrhagic shock. J Appl Physiol 1996;81:707-15.
189. Thiemermann C, Wu CC, Piper J, Chen SJ, Szabó C, Vane JR. Aminoguanidine attenuates the delayed circulatory failure in endotoxic and haemorrhagic shock in the anaesthetized rat. Can J Physiol Pharmacol 1994;(1 Suppl):471.
190. Vargaftig B, Braquet P. PAF-acether today: relevance for acute experimental anaphylaxis. Br Med Bull 1987;43:312-35.
191. DeWeck A. Chemical mediators of allergic reactions. Folia Allergol Immunol Clin 1975;22:505-13.
192. Piper P. Anaphylaxis and the release of active substances in the lungs. Pharmacol Ther 1977;3:75-98.
193. Szabó C, Wu C, Thiemermann C, Vane J. Role of constitutive and inducible nitric oxide synthases in the cardiovascular response in systemic anaphylaxis. Br J Pharmacol 1993;110:31P.
194. Osada S, Ichiki H, Oku H, Ishiguro K, Kunimoto M, Semma M. Participation of nitric oxide in mouse anaphylactic hypotension. Eur J Pharmacol 1994;252:347-50.
195. Moritoki H, Hisayama T, Takeuchi S, Miyano H, Kondoh W. Involvement of nitric oxide in the PAF-induced relaxation of rat thoracic aorta. Br J Pharmacol 1992; 107: 196-201.
196. Krstic M, Stepanovic R, Krstic S, Katusic Z. Endothelium-dependent relaxation of the rat renal artery caused by activation of histamine H1 receptors. Pharmacology 1989;38:113-20.
197. Pawloski J, Chapnick B. Leukotrienes C4 and D4 are potent endothelium-dependent relaxing agents in canine splanchnic venous capacitance vessels. Circ Res 1993;73:395-404.
198. G-nitro-L-arginine methyl ester, improves survival in anaphylactic shock. Eur J Pharmacol 1991;203:125-7.
199. Mitsuhata H, Takeuchi H, Saitoh J, Hasome N, Horiguchi Y, Shimizu R. An inhibitor of nitric oxide synthase, N omega-nitro-L-arginine-methyl ester, attenuates hypotension but does not improve cardiac depression in anaphylaxis in dogs. Shock 1995;3:447-53.
200. Mitsuhata H, Saitoh J, Takeuchi H, Hasome N, Horiguchi Y, et al. Production of nitric oxide in anaphylaxis in rabbits. Shock 1994;2:381-4.
201. Mitsuhata H, Shimizu R, Yokoyama M. Role of nitric oxide in anaphylactic shock. J Clin Immunol 1995;15:277-83.
202. Weiss R, Donehower R, Wiernik P, et al. Hypersensitivity reactions from taxol. J Clin Oncol 1990;8:1263-8.
203. Weiss R, Donehower R, Wiernik P. Hypersensitivity reactions. Semin Oncol 1990;19: 458-77.
204. Dye D, Watkins J. Suspected anaphylactic reaction to Cremophor. Br J Med 1980;280: 1353.
205. Lorenz W, Reimann H, Schmal A. Histamine release in dogs by Cremophor EL and its derivatives: oxethylated oleic acid is the most effective constituent. Agents Actions 1977;7:63-7.
206. Kirikae F, Kirikae T, Qureshi N, Takayama K, Morrison D, et al. CD 14 is not involved in Rhodobacter sphaeroides di-phosphoryl lipid A inhibition of tumor necrosis factor alpha and nitric oxide induction by Taxol in murine macrophages. Infect Immun 1995;63:486-97.
207. Ding A, Porteu F, Sanchez E, Nathan C. Shared action of endotoxin and Taxol on TNF receptors and TNF release. Science 1990;248:370-2.
208. Bogdan C, Ding A. Taxol, a microtubule-stabilizing anti-neoplastic agent induces expression of tumor necrosis factor and interleukin-1 in macrophages. J Leukoc Biol 1992;52:119-21.
209. Kirikae T, Ojima I, Kirakae F, Ma Z, Kuduk S, Slater J, et al. Structural requirements of taxoids for nitric oxide and tumor necrosis factor production by macrophages. Biochem Biophys Res Commun 1996;227:227-35.
210. Blaise G, Sill J, Nugent M, VanDyke R, Vanhoutte P. Isoflurane causes endothelium-dependent inhibition of contractile responses of canine coronary arteries. Anesthesiology 1987;67:513-7.
211. Greenblatt E, Loeb A, Longnecker D. Endothelium-dependent circulatory control-a mechanism for differing peripheral vascular effects of isoflurane versus halothane. Anesthesiology 1992;77:1178-85.
212. G-nitro-L-arginine. Eur J Pharmacol 1991;198:183-8.
213. G-nitro-L-arginine methyl ester prevents cerebral hyperemia by inhaled anesthetics in dogs. Anesth Analg 1993;77:891-7.
214. Muldoon S, Hart J, Bowen K, Freas W. Attenuation of endothelium-mediated vasodilation by halothane. Anesthesiology 1988;68:31-7.
215. Stone D, Johns R. Endothelium-dependent effects of halothane, enflurane, and isoflurane on isolated rat aortic vascular rings. Anesthesiology 1989;71:126-32.
216. Petros A, Bogle R, Pearson J. Propofol stimulates nitric oxide release from cultured porcine aortic endothelial cells. Br J Pharmacol 1993;109:6-7.
217. Doursout M-F, Kilbourn R, Chelly J. Role of nitric oxide in the vasodilation induced by propofol. Anesthesiology 1994;81:A767.
218. Chelly J, Oguchi M, Liang Y, Hartley C, Doursout M-F. Role of the Intralipid solvent in the propofol-induced nitric oxide stimulation. Anesthesiology 1996;85:A555.
219. Steinberg J, Kapelanski D, Olson J. Cytokine and complement levels in patients undergoing bypass. J Thorac Cardiovasc Surg 1993;106:1008-16.
220. Gulick T, Chung M, Pieper S. Interleukin-1 and tumor necrosis factor inhibit cardiac beta-adrenergic responsiveness. Proc Natl Acad Sci USA 1989;86:6753-7.
221. Berkowitz D, Richardson C, Elliott D, Leslie J, Schwinn D. Hypotension resistant to therapy with alpha receptor agonists complicating cardiopulmonary bypass: lithium as apotential cause. Anesth Analg 1996;82:1082-5.
222. Mayumi H, Toshima Y, Tokunaga K. Pretreatment with H2 blocker famotidine to ameliorate protamine-induced hypotension in open-heart surgery. J Cardiovasc Surg 1992;33:738-45.
223. Kovách A, Faragó M, Lohinai Z, et al. Changes of contractile and endothelium-dependent relaxant responses following a 2-hour hemorrhagic hypotension in cats: regional differences. J Cardiovasc Pharmacol 1991;17(3 Suppl 3):S198-206.
224. Kovách A, Szabó C, Faragó M, Lohinai Z, Fehér E. Effect of hemorrhagic hypotension on cerebrovascular reactivity and ultrastructure in the cat. Stroke 1991;22:1541-7.
225. Szabó C, Faragó M, Horváth I, Lohina IZ, Kovách A. Hemorrhagic hypotension impairs endothelium-dependent relaxations in the renal artery of the cat. Circ Shock 1992;36:238-41.
226. Szabó C, Csáki C, Benyó Z, Reivich M, Kovách A. Role of the L-arginine-nitric oxide pathway in the changes in cerebrovascular reactivity following hemorrhagic hypotension and re-transfusion. Circ Shock 1992;37:307-16.
227. Wang P, Ba Z, Chaudry I. Endothelial cell dysfunction occurs very early following trauma-hemorrhage and persists despite fluid resuscitation. Am J Physiol 1995;268: H1390-406.
228. Wang P, Zheng F, Chaudry I. Endothelial cell dysfunction occurs after hemorrhage in non-heparinized but not in heparinized models. J Surg Res 1993;54:499-506.
229. Parker J, Adams H. Selective inhibition of endothelium-dependent vasodilator capacity by Escherichia-coli endotoxaemia. Circ Res 1993;72:539-51.
230. Umans J, Wylam M, Samsel R, Edwards J, Schumacker P. Effects of endotoxin in vivo on endothelial and smooth-muscle function in rabbit and rat aorta. Am Rev Respir Dis 1993;148:1638-45.
231. Myers P, Zhong Q, Jones J, Tanner M, Adams H, Parker J. Release of EDRF and NO in ex vivo perfused aorta: inhibition by in vivo E. coli endotoxemia. Am J Physiol 1995;268:H955-61.
232. Csáki C, Szabó C, Benyó Z, Reivich M, Kovách A. Activated neutrophils inhibit cerebrovascular endothelium-dependent relaxation in vitro. Life Sci 1991;49:1087-94.
233. Wang P, Ba Z, Stepp K, Chaudry I. Pentoxifylline attenuates the depressed endothelial cell function and vascular muscle contractility following trauma and hemorrhagic shock. J Trauma 1995;39:121-6.
234. Lefer A, Lefer D. Pharmacology of the endothelium in ischemia reperfusion and circulatory shock. Ann Rev Pharmacol Toxicol 1993;33:71-90.
235. Akopov S, Grigorian M, Gabrielian E. The endothelium-dependent relaxation of human middle cerebral artery: effect of activated neutrophils. Experientia 1992;48:34-6.
236. Szabó C, Csáki C, Benyó Z, Marczis J, Reivich M, Kovách A. Effect of Superoxide dismutase on hemorrhagic hypotension and re-transfusion evoked middle cerebral artery endothelial dysfunction. Circ Shock 1994;44:104-10.
237. Az-ma T, Fujii K, Yuge O. Self-limiting enhancement by nitric oxide of oxygen free radical induced endothelial cell injury: evidence against the dual action of nitric oxide as hydroxyl radical donor/scavenger. Br J Pharmacol 1996;119:455-62.
238. Ischiropoulos H, al-Mehdi A, Fisher A. Reactive species in ischemic rat lung injury: contribution of peroxy-nitrite. Am J Physiol 1995;269:L158-64.
239. Estrada C, Gomez C, Martin C, Moncada S, Gonzalez S. Nitric oxide mediates tumor necrosis factor-alpha cytotoxicity in endothelial cells. Biochem Biophys Res Comm 1992;186:475-82.
240. Fatehi-Hassanabad Z, Burns H, Aughey E, Paul A, Plevin R, Parratt J, et al. Effects of 1-canavanine, an inhibitor of inducible nitric oxide synthase, on endotoxin mediated shock in rats. Shock 1996;6:194-200.
241. Lefer A. Properties of cardioinhibitory factors produced in shock. Fed Proc 1978;37: 2734-40.
242. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo J. Tumor necrosis factor alpha and interleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996;183:949-58.
243. Grocott-Mason R, Fort S, Lewis M, Shah A. Myocardial relaxant effect of exogenous nitric oxide in isolated ejecting hearts. Am J Physiol 1994;266:H1699-705.
244. Schulz R, Triggle C. Role of NO in vascular smooth muscle and cardiac muscle function. Trends Pharmacol Sci 1994;15:255-9.
245. Schulz R, Smith J, Lewis M. Nitric oxide synthase in cultured endothelial cells of the pig. Br J Pharmacol 1991;104:21-4.
246. 2+ independent nitric oxide synthase in the myocardium. Br J Pharmacol 1992;105:575-80.
247. Smith J, Radomski M, Schulz R, Moncada S, Lewis M. Porcine ventricular endothelial cells in culture express the inducible form of nitric oxide synthase. Br J Pharmacol 1993;108:1107-10.
248. Kelly R, Balligand J, Smith T. Nitric oxide and cardiac function. Circ Res 1996;79: 363-80.
249. Simmons W, Closs E, Cunningham J, Smith T, Kelly R. Cytokines and insulin induce cationic amino acid transporter (CAT) expression in cardiac myocytes: regulation of L-arginine transport and no production by CAT-1, CAT-2A, and CAT-2B. J Biol Chem 1996;271:11694-702.
250. McKenna T, Li S, Tao S. PKC mediates LPS- and phorbol-induced cardiac cell nitricoxide synthase activity and hypo-contractility. Am J Physiol 1995;269:H1891-8.
251. Singh K, Balligand J, FischerT, SmithT, Kelly R. Regulation of cytokine-inducible nitric oxide synthase in cardiac myocytes and microvascular endothelial cells: role of extracellular signal-regulated kinases 1 and 2 (ERK1/ERK2) and STAT1 alpha. J Biol Chem 1996;271:1111-7.
252. LaPointe M, Sitkins J. Mechanisms of interleukin-1 beta regulation of nitric oxide synthase in cardiac myocytes. Hypertension 1996;27:709-14.
253. Hattori Y, Kasai K, So S, Hattori S. Banba N, Shimoda S. Effects of calcium channel antagonists on the induction of nitric oxide synthase in cultured cells by immunostimulants. Life Sci 1995;57:1833-40.
254. Matsumori A, Okada I, Shioi T, Furukawa Y, Nakamura T, Ono K, et al. Inotropic agents differentially inhibit the induction of nitric oxide synthase by endotoxin in cultured macrophages. Life Sci 1996;59:121-5.
255. Finkel M, Oddis C, Jacob T, Watkins S, Hattler B, Simmons R. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
256. Roberta A, Vodovotz Y, Roche N. Role of nitric oxide in antagonistic effects of transforming growth factor-beta and interleukin-1 beta on the beating of rat cultured cardiac myocytes. Mol Endocrinol 1992;6:1921-30.
257. Evans H, Lewis M, Shah A. Interleukin-1 beta modulates myocardial contraction via dexamethasone sensitive production of nitric oxide. Cardiovasc Res 1993;27:1486-90.
258. Balligand J, Ungureanu D, Kelly R, Kobzik E, Pimentai D, Michel T, et al. Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. J Clin Invest 1993;91:2314-9.
259. Balligand J, Ungureanu-Longrois D, Simmons W, et al. Cytokine-inducible nitric oxide synthase (iNOS) expression in cardiac myocytes: characterization and regulation of iNOS expression and detection of iNOS activity in single cardiac myocytes in vitro. J Biol Chem 1994;269:27580-8.
260. Tao S, McKenna T. In vitro endotoxin exposure induces contractile dysfunction in adult rat cardiac myocytes. Am J Physiol 1994;267:H1745-52.
261. Stein B, Frank P, Schmitz W, Scholz H, Thoenes M. Endotoxins and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase. J Mol Cell Cardiol 1996;28:1631-9.
262. Ungureanu-Longrois D, Balligand J, Kelly R, Smith T. Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes. J Mol Cell Cardiol 1995;27:155-67.
263. Szabó C, Thimermann C, Vane JR. Inhibition of the production of nitric oxide and vasodilator prostaglandins attenuates the cardiovascular response to bacterial endotoxin in adrenalectomized rats. Proc R Soc B Biol Sci 1993;253:233-8.
264. Vodovotz Y, Geiser A, Chesler E, Letterio J, Campbell A, Lucia M, et al. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor beta 1 null mouse. J Exp Med 1996;183:2337-42.
265. Salter M, Knowles R, Moncada S. Widespread tissue distribution, species distribution and changes in activity of Ca(2+)-dependent and Ca(2+)-independent nitric oxide synthases. FEBS Lett 1991;291:145-9.
266. Szabó C, Mitchell J, Thiemermann C, Vane J. Nitric oxide mediated hyporeactivity to noradrenaline precedes nitric oxide synthase induction in endotoxin shock. Br J Pharmacol 1993;108:786-92.
267. Buttery L, Evans T, Springall D, Carpenter A, Cohen J, Polak J. Immunochemical localization of inducible nitric oxide synthase in endotoxin-treated rats. Lab Invest 1994;71:755-64.
268. Nagasaki A, Gotoh T, Takeya M, Yu Y, Takiguchi M, Matsuzaki H, et al. Co-induction of nitric oxide synthase, argininosuccinate synthetase, and argininosuccinate lyase in lipopolysaccharide-treated rats: RNA blot, immunoblot, and immunohistochemical analyses. J Biol Chem 1996;271:2658-62.
269. Luss H, Watkins S, Freeswick P, Imro A, Nussler A, BilliarT, et al. Characterization of inducible nitric oxide synthase expression in endotoxemic rat cardiac myocytes in vivo and following cytokine exposure in vitro. J Mol Cell Cardiol 1995;27:2015-29.
270. Brady A, Poole-Wilson P, Harding S, Warren J. Nitric oxide production within cardiac myocytes reduces their contractility in endotoxemia. Am J Physiol 1992;263: H1963-6.
271. Klabunde R, Coston A. Nitric oxide synthase inhibition does not prevent cardiac depression in endotoxic shock. Shock 1995;3:73-8.
272. Schulz R, Panas D, Catena R, Moncada S, Olley P, Lopaschuk G. The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha. Br J Pharmacol 1995;114:27-34.
273. Panas D, Szabó C, Schulz R. Selective inhibition of inducible nitric oxide synthase reduces cytokine-mediated cardiac depression in isolated working hearts. Circulation 1996;94:516-20.
274. Sun X, Wei S, Szabó C, Dusting G. Depression of the inotropic action of isoprenaline by nitric oxide synthase induction in rat isolated hearts. Eur J Pharmacol. In press.
275. Schulz R, Dodge KL, Lopaschuj G, Clanachan AS. Peroxynitrite impairs cardiac contractile function by decreasing cardiac efficiency. Am J Physiol. (In press).
276. Xie Y, Shen W, Zhao G, Xu X, Wolin M, Hintze T. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res 1996;79:381-7.
277. Gross W, Bak M, Ingwall J, Arstall M, Smith T, Balligand J. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci USA 1996;93:5604-9.
278. G-nitro-L-arginine infusion in porcine endotoxin shock. Crit Care Med 1995;23:909-18.
279. Offner P, Robertson F, Pruitt B. Effects of nitric oxide synthase inhibition on regional blood flow in a porcine model of endotoxic shock. J Trauma 1995;39:338-43.
280. Statman R, Cheng W, Cunningham J, Henderson J, Damiani P, Siconolfi A, et al. Nitric oxide inhibition in the treatment of the sepsis syndrome is detrimental to tissue oxygenation. J Surg Res 1994;57:93-8.
281. G-methy-L-arginine, an inhibitor of nitric oxide formation, acts synergistically with dobutamine to improve cardiovascular performance in endotoxemic dogs. Crit Care Med 1994;22:1835-40.
282. Avontuur J, Bruining H, Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ Res 1995;76:418-25.
283. Zhang H, Rogiers P, Preiser J, Spapen H, Manikis P, Metz G, et al. Effects of methylene blue on oxygen availability and regional blood flow during endotoxic shock. Crit Care Med 1995;23:1711-21.
284. Herbertson M, Werner H, Walley K. Nitric oxide synthase inhibition partially prevents decreased LV contractility during endotoxemia. Am J Physiol 1996;270: H1979-84.
285. Liaudet L, Feihl F, Rosselet A, Markert M, Hurni J, Perret C. Beneficial effects of l-canavanine, a selective inhibitor of inducible nitric oxide synthase, during rodent endotoxaemia. Clin Sci 1996;90:369-77.
286. Benyó Z, Kiss G, Szabó C, Csáki C, Kovách A. Importance of basal nitric oxide synthesis in the regulation of myocardial blood flow. Cardiovasc Res 1991;25:700-3.
287. Southan G, Szabó C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996;51:383-4.
288. Griffith O, Park K, Aisaka K, Gross S. The role of plasma arginine in nitric oxide synthesis: studies with arginase-treated guinea pigs and rats. In: Moncada S, Marletta M, Hibbs J, Higgs E, editors. The biology of nitric oxide, vol 1. Physiological and clinical aspects. London: Portland Press; 1992. p. 6-10.
289. Nussler A, Billiar T, Liu Z, Morris S. Co-induction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. J Biol Chem 1994;269: 1257-61.
290. Hattori Y, Campbell E, Gross S. Argininosuccinate synthetase mRNA and activity are induced by immunostimulants in vascular smooth muscle: role in the regeneration or arginine for nitric oxide synthesis. J Biol Chem 1994;269:9405-8.
291. Pacitti A, Copeland E, Souba W. Stimulation of hepatocyte system Y+ mediated L-arginine transport by an inflammatory agent. Surgery 1992;112:403-11.
292. Gold ME, Wood KS, Buga GM, Byrns RE, Ignarro LJ. L-arginine causes whereas 1-argininosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxation. Biochem Biophys Res Commun 1989;161:536-43.
293. Gold ME, Wood KS, Byrns RE, Buga GM, Ignarro LJ. L-arginine-dependent vascular smooth muscle relaxation and cGMP formation. Am J Physiol 1990:259: H1813-21.
294. Schott C, Gray G, Stoclet J. Dependence of endotoxin-induced vascular hyporeactivity on extracellular L-arginine. BrJ Pharmacol 1993;108:38-43.
295. Bone H, Traber L, Schenarts P, Spaulding T, Traber D. Hemodynamic effects of pyridoxylated hemoglobin polyoxyethylene conjugate (PHP) in conscious sheep during septic shock. Anesthesiology 1995;83:A232.
296. Yabuki A, Yamaji K, Ohki H, Iwashita Y. Characterization of a pyridoxylated hemoglobin polyoxyethylene conjugate as a physiological oxygen carrier: pyridoxylated hemoglobin polyoxyethylene conjugate (PHP). Transfusion 1990;30:516-20.
297. Malchesky P, Takahashi T, Iwashita K, Harasaki H. Nose Y. Conjugated human hemoglobin as a physiological oxygen carrier: pyridoxylated hemoglobin polyoxyethylene conjugate (PHP). Artif Organs 1990;13:442-50.
298. Bone H, Booke M, Traber L, Spaulding T, Traber D. Nitric oxide synthase inhibition versus nitric oxide scavenging in sepsis. Circulation 1995;92:1-46.
299. Fisher S, Bone H, Traber D. Effects of hemoglobin in sepsis. In: Vincent J, editor. The yearbook of intensive care and emergency medicine 1997. Brussels: Springer-Verlag:424-44.
300. Bone H, Schenarts P, McGuire R, Cindrick L, Fisher S, Booke M, et al. Modified hemoglobin causes a redistribution of blood flow in the myocardium during ovine sepsis. Crit Care Med 1996;24:A99.
301. Petros A, Bennett D, Vallance P, Effects of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991;338:1557-8.
302. G-monomethyl-L-arginine, an inhibitor of nitric oxide synthase. Intensive Care Med 1993;19:227-31.
303. G-monomethyl-L-arginine, an inhibitor of nitric oxide production, reverses interleukin-2 mediated hypotension in humans. Crit Care Med 1995;23:1018-24.
304. Fonseca G, Kilbourn R. Cardiovascular alterations associated with interleukin-2 therapy. In: Fink MP, Payen D, editors. Role of nitric oxide in sepsis and ARDS. Berlin: Springer-Verlag; 1995.
305. G methyl-L-arginine in cancer patients with shock. Endothelium 1995;3(suppl):57.
306. Locker G, Burgmann H, Staudinger T, Knapp S, Laczika K, Frass M. Fatal cardiac side effect of L-NMMA? Crit Care Med 1996;24:1930.
307. G methyl arginine HCL) in an open label, dose escalation study of patients with septic shock. Presented at the 8th European Congress of Intensive Care Medicine; Athens, Greece, Oct. 18-22, 1995.
308. ω-mono-methyl-L-arginine in ovine sepsis: should a continuous infusion be initiated by bolus? Crit Care Med 1995;23: A164.
309. Rhea G, BodenhamA, Mallick A, Prebelski R, Daly E. Vasopressor effects of diaspirin cross-linked hemoglobin (DCLHb) in critically ill patients [abstract]. Crit Care Med 1996;24:A39.
310. Bone H, Booke M, Schenarts P, O'Connor M, Traber L, Traber D. Comparison of different doses of pyridoxylated hemoglobin polyethylene conjugate in the treatment of hyperdynamic sepsis. Crit Care Med 1996;24:A27.
311. Preiser J, Lejeune P, Roman A, Carlier E, De Backer D, Leeman M, et al. Methylene blue administration in septic shock: a clinical trial. Crit Care Med 1995;23:259-64.
312. Gachot B, Bedos J, Veber B, Wolff M, Regnier B. Short-term effects of methylene blue on hemodynamics and gas exchange in humans with septic shock. Intensive Care Med 1995;21:1027-31.
313. Schneider F, Lutun P, Hasselman M, Stoclet J, Tempe J. Methylene blue increases systemic vascular resistance in human septic shock. Intensive Care Med 1992;18:309-11.
314. Thoenes M, Forstermann U, Tracey W, Bleese N, Nussler A, Scholz H, et al. Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol 1996;28:165-9.
315. Haywood G, Tsao P, von der Leyen H, et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 1996;93:1087-94.
316. Lewis N, Tsao P, Rickenbacher P, et al. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 1996;9:720-9.
317. Daemen-Gubbels C, Groeneveld P, Groeneveld A, van Kamp G, Bronsveld W, Thijs L. Methylene blue increases myocardial function in septic shock. Crit Care Med 1995;23:1363-70.